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 Abstract: 
While cancer immunotherapy presents the possibility of safe and effective treatments, a 
variety of factors may reduce the effectiveness of existing immunotherapies. Of particular note is 
the ability of cancer to activate cellular signaling pathways that ultimately suppress inflammatory 
responses. Two cell types thought to mediate cancer-related immunosuppression are 
myeloid-derived suppressor cells (MDSCs) and dendritic cells (DCs). The TAM family of 
receptor tyrosine kinases (​Tyro3​, ​Axl​, and ​Mer​) is implicated in regulation of the immune system 
and the clearance of apoptotic cells. We hypothesize that TAM RTK signaling, particularly 
MerTK signaling, contributes to cancer-related immunosuppression by regulating the ability of 
MDSCs and DCs to suppress or stimulate the adaptive immune response. To determine the role 
of TAM RTKs in MDSC and DC function, we measured the expression level of various RNAs 
and proteins associated with the regulation of the immune system in MDSCs extracted from 
Mer​-/-​ ​mice and DCs extracted from ​Tyro3​-/-​, ​Axl​-/-​, and ​Mer​-/-​ mice. MDSCs were also treated 
with TAM RTK inhibitors UNC 4198 and UNC 2371 developed by the Earp Lab. We also 
compare the ability of TAM knock-out and control DCs to stimulate T-cell proliferation. Due to 
the known role of nitric oxide signaling and arginase activity in MDSC-mediated suppression of 
the immune response, the immunosuppressive capabilities of MDSCs of both wildtype and TAM 
RTK knockout genotypes were assessed with enzymatic assays for nitric oxide synthase (iNOS), 
reactive oxygen species (ROS), and arginase activity. We found that TAM RTK knockout 
MDSCs exhibited significant changes in RNA and protein expression and increased iNOS and 
arginase activity, indicating they have a reduced immunosuppressive capacity. Analysis of TAM 
RTK knockout DCs yielded mixed results, though results consistent with literature supported the 
immunosuppressive role of TAM RTK signaling in DCs as well, though some contradictory 
results in T-cell proliferation and mRNA expression will require further study. Thus, the role of 
TAM RTK signaling in immune responses may be more complex than previously believed, but 
inhibition of TAM RTKs holds promise as a means of bolstering the immune response to cancer 
and providing treatment to individuals with the disease. 
 
Introduction​: 
Myeloid Derived Suppressor Cells and Dendritic Cells: ​As scientists and clinicians continue to 
place a greater emphasis on the use of immunotherapy in cancer treatment, it is important to 
better define the role of different cell types in the immune response against cancer. 
Myeloid-derived suppressor cells (MDSCs) are a set of immature immune cells noted for their 
ability to regulate the inflammatory response in the context of cancer and other diseases. MDSCs 
consist of both granulocytic and monocytic subsets, which eventually develop into mature 
granulocytes and monocytes, respectively. Both subsets express high levels of CD11b, and can 
be distinguished from each other by the expression of the markers Ly6G and Ly6C, with 
granulocytic MDSCs having the phenotype Cd11b​+​Ly6G​+​Ly6C​low​ and monocytic MDSCs 
possessing the phenotype CD11b​+​Ly6G​-​Ly6C​high 1​. These cells primarily reduce CD8​+​ T-cell 
 
 activity through the production of nitric oxide by inducible nitric oxide synthase (iNOS), which 
occurs primarily in monocytic MDSCs;the depletion of arginine in the local environment via 
arginase activity, which is more prominent in granulocytic MDSCs; and the secretion of reactive 
oxygen species (ROS) by both subsets.​1​ All of these functions are associated with 
downregulation of the adaptive and innate immune system in the tumor microenvironment, with 
ROS and NO react to form radicals capable of nitrosylating, and thus inhibiting, T-cell receptors, 
and arginase activity depleting arginine necessary for cytotoxic T-cell function ​2​ ​3​ ​4​. Dendritic 
cells (DCs), another component of the immune system, function as the primary 
antigen-presenting cells of the immune system, utilizing both the MHCI and MHCII systems of 
signaling proteins to activate the adaptive immune response.​5​ DCs stimulate the CD8​+​ T-cell 
response to cancer cells, but they are also capable of tolerizing the immune system to certain 
antigens, which can reduce ability of T-cells to fight the disease.​5​ Both MDSCs and DCs act on 
the immune system, and are controlled by other cells through different extracellular signaling 
pathways. 
TAM Family Receptor Tyrosine Kinases: ​The TAM-family of receptor tyrosine kinases (TAM 
RTKs) is one of these networks; the binding of the ligands Gas6, which binds to Tyro3, Axl and 
Mer TK, and Protein S, which binds to the extracellular domains of Tyro3 and MerTK forms a 
bridge between the receptors and exposed phosphatidyl serine on apoptotic cell membranes, 
leading to the activation of intracellular signaling cascades such as the JAK/STAT3 and 
MAPK/ERK pathways associated with increased cell metabolism and proliferation, and altered 
function in many cell types expressing the receptors. Because these proteins are associated with 
the suppression of the immune response ​6​ and are expressed in many immune cells, including 
monocytes, granulocytes (which develop from bone marrow precursors) and DCs,​7 8​ TAM RTKs 
likely are involved in regulating their response to cancer. 
The immunosuppressive nature of the TAM RTKs makes them suitable targets for small 
molecule inhibition. To this extent, our collaborators in the UNC Eshelman School of Pharmacy 
Center for Integrative Chemical Biology and Drug Discovery, have created a panel of TAM 
RTK specific small molecule inhibitors. The inhibitors are designed to preferentially bind to one 
or more TAM receptor. For our studies, we have used UNC2371 and UNC4198. UNC2371 is a 
MerTK specific inhibitor (IC50 MerTK= 1.3 nM, Axl= 15 nM, Tyro3=7 nM) while UNC4198 is 
a MerTK/Tyro3-inhibitor (IC50 MerTK= 0.98 nM, Axl= 5.5 nM, Tyro3= 0.56 nM). While 
inhibition of TAM RTK signaling holds promise as a means of treating cancer by bolstering the 
immune response, the effects of TAM RTK inhibition must be characterized before inhibitors 
can be used in medicine. 
Preliminary results indicate that inhibition of TAM RTK signaling reduces the ability of 
MDSCs to produce nitric oxide and arginase, but the underlying mechanisms behind this activity 
remain unknown (Holtzhausen, unpublished data). Since cancer cells are capable of upregulating 
the expression of TAM RTK ligands Gas6 and Protein S,​9 10 11​ TAM RTK signaling is believed to 
contribute to cancer-related suppression of the immune system. Inhibition of these receptors 
 
 could, therefore, reduce this capacity of cancer to reduce the inflammatory response, improving 
the ability of the immune system to fight the disease. DCs also express TAM RTKs in relatively 
high quantities, so signaling through these receptors likely affects many cell processes, possibly 
including the ability of DCs to present antigens to CD8​+ ​T-cells to stimulate a response.​6 
Cross-presentation, or the ability of DCs to present exogenous antigens to cells of the adaptive 
immune system through the MHCI system instead of the usual MHCII system, is important in 
activating the anti-cancer CD8​+​ T-cell response.​12​ On the other hand, tolerogenic DCs reduce the 
inflammatory response through mechanisms involving production of inhibitory cytokines 
coincident with activation of CD4​+​ T-regulatory cells.​13​ In cancer, DCs continually take up 
antigen from apoptotic tumor cells and present these antigens to T-cells to trigger an anti-cancer 
immune response. However, signaling molecules produced by the cancer cells are capable of 
modifying the signals from DCs to CD8​+​ T-cells, causing the DCs to inhibit cytotoxic T-cell 
activity towards antigens associated with the cancer cells instead of promoting it. This shift is 
accompanied by a change in the production of cytokines by dendritic cells, changing from the 
production of signals such as interferon-γ, which is associated with increased cross-presentation 
and greater CD8​+​ T-cell activity, to inhibitory cytokines such as IL-10 and IL-12. These cells 
suppress CD8​+​ T-cells and reduce the immune response,​14​ so potential cancer treatments would 
focus on reducing the tolerogenic activity of DCs while promoting cross-presentation and 
activation of CD8​+​ T-cells. 
TAM RTK Inhibition and Cancer Treatment: ​Based on the preliminary data, inhibition or 
knockout of TAM RTKs in MDSCs reduces the ability of these cells to suppress the immune 
response in the context of cancer. Detectable changes in expression and phosphorylation of 
intracellular signaling proteins were predicted to alter the immunosuppressive functions of 
MDSCs with TAM RTK inhibition. Assuming that in DCs, TAM RTK signaling also suppresses 
the immune response to cancer, knockout of the one or more TAM RTKs was expected to 
increase the ability of DCs to stimulate CD8​+​ T-cells and reduce the tolerizing mechanism. DCs 
with a ​Tyro3​-/-​, ​Axl​-/-​, or ​Mer​-/-​ genotype would also show changes in the expression of RNA and 
proteins associated with antigen-presenting and immunostimulatory activity. 
 The capacity of MDSCs to inhibit other immune cells depends on the production of NO 
and ROS, along with the depletion of arginine caused by arginase activity; direct measurement of 
these functions through enzymatic assays would have indicated a reduction in all three if TAM 
RTK signaling does contribute to their immunosuppressive capability. Changes in the expression 
and phosphorylation of proteins associated with MDSC activity, including P38/p-P38 and NFκB/ 
p-NFκB would also have evinced the reduction of MDSC-mediated immunosuppression 
associated with knockout of TAM RTKs. We used western blots to detect these changes in 
expression and illustrate the underlying mechanism regulating suppressive activity in MDSCs. 
 Because the contribution of DCs to the anti-cancer immune response primarily comes 
from their ability to induce the activity of CD8​+​ and CD4​+​ T-cells, proliferation assays were used 
to measure the effect of TAM RTK suppression. An increased ability of DCs to stimulate CD8​+ 
 
 T-cell proliferation, along with decreased proliferation of CD4​+​ T-cells was observed. Moreover, 
TAM RTK knockout DCs were expected to demonstrate a decreased production of inhibitory 
cytokines along with an upregulation in the expression of proteins associated with DC-mediated 
activation of the inflammatory response via cross-presentation.​15​ ​16​ ​17​ ​18​ ​19 20​ ​21​ ​22​ ​23​ ​24​ ​25​ These 
changes were detected via real-time quantitative PCR (for measuring changes in RNA 
expression) and by Western blot (for measuring changes in protein expression). 
 
Methods: 
WT and Mer​-/-​ MDSCs: ​Mice from both WT and ​Mer​-/-​ strains of C57BL/6 mice 
(Jackson Labs) were injected with syngeneic B16 melanoma cells, and kept until tumor diameter 
reached 15 mm. The spleens of the mice were then harvested and splenocytes were extracted by 
mechanical disaggregation of spleens followed by lysing of erythrocytes in the single-cell 
suspension. ​CD11b​+​ cells were isolated from the resulting suspensions using CD11b-conjugated 
magnetic beads (Miltenyi Biotec), and M-MDSCs and G-MDSCs were separated from ​CD11b​+ 
myeloid cells using fluorescence activated cell sorting based on the phenotypic expression of 
markers ​Cd11b​+​Lys6G​-/​-​Lys6C​high​ (M-MDSC) and ​Cd11b​+​Lys6G​high​Lys6C​low​ (G-MDSC). The cell 
sorting (Alisha Holtzhausen) was performed using commercially-available antibodies (BD 
Pharmingen) and a FACSAria III cell sorter (BD Biosciences), purifying populations of interest 
to 97% purity. 
WT and TAM RTK-null DCs:​ Dendritic cells were obtained from the spleens of WT, 
Tyro3​-/-​, ​Axl​-/-​, and ​Mer​-/-​ strains of C57/B6 mice (Jackson Labs). Cells were purified using a 
CD11c​ magnetic bead positive selection kit (Stem Cell Technologies), and isolated DCs were 
incubated in 96-well plates for three days before use in experiments. Purity of the cells was 
checked using flow cytometry to assess expression of ​CD11b ​and ​MHCII​. 
T-Cell Proliferation Assay:​  Murine ​CD11c​+​ ​DCs were purified as described above using 
an Easy Sep magnetic bead positive selection kit (Stem Cell Technologies). OT-1 ​CD4​+​ ​T-cells 
and ​CD8​+​ T-cells extracted from the spleens of OT-1 mice (Jackson Labs) were isolated using an 
Easy Sep kit to select for the expression of the respective protein markers (Stem Cell 
Technologies). B16 cells were treated with 10 micromolar staurosporine overnight to induce 
apoptosis, and ​CD11c​+​ ​DCs were incubated with these apoptotic cells in the presence of OVA 
peptide for two days  prior to co-culture with OT-1 ​CD8​+​ ​T-cells. As a control for 
antigen-presenting activity, a sample of ​CD11c​+​ ​DCs was co-cultured with both OVA peptide 
and OT-1 ​CD8​+​ ​T-cells simultaneously and allowed to incubate for the same amount of time. 
DCs were incubated with ​CD8​+​ T-cells in both 40,000:200,000 and 40,000:240,000 DC:T-Cell 
ratios, and DCs were incubated with ​CD4​+​ T-cells in a 40,000:240,000 ratio. ​CD4​+​ T-cell 
activity was assessed by culturing ​CD4​+​ cells with ​CD11c​+​ DCs for two days.  A CyQuant T-cell 
Proliferation Assay Kit was used to quantify the cells by measuring fluorescence on a 508/527 
nm wavelength. 
 
 qRT-PCR:​ DCs obtained from both WT and TAM RTK knockout mice using the method 
described above were processed using a Qiagen RNeasy Mini Kit to obtain RNA. qRT-PCR was 
performed using standard concentrations 1 𝜇mol RNA from DCs with a Taqman RNA-to-Ct 
1-Step Kit (ThermoFisher Scientific) and commercially obtained probes for ​Tyro3​, ​Axl​, ​Mer​, 
Gas6​, and ​ProS ​(Applied Bioscience). For these genes, RNA standards varying in concentration 
(1,666-21 fg) were used as controls. Expression of other genes (​Akt1​, ​Ccl2​, ​MyD88​, ​IFNγ​, ​IL-10​, 
IL-12​, ​Traf6​, ​Vegf​, ​Ido​, ​PD-L1​, ​PGE-2​) was quantified by using a Power SYBR Green Master 
Mix protocol to compare expression of these genes to GAPDH as a control (ThermoFisher 
Scientific). A 𝛥𝛥Ct method was used to analyze the results and compare TAM RTK knockout 
cells to WT. All PCR was performed with controls and samples in triplicate. 
 Arginase Assay: ​MDSCs obtained using the method described above were lysed using 
buffer containing MnCl​2​ in a 100:1 water-Tris solution with a Roche complete mini protease 
inhibitor cocktail tablet (Roche Pharmaceuticals) for 10 minutes. After lysing, lysates were 
incubated with 0.5M L-arginine solution at 37​o​C for 120 minutes. The arginase reaction, which 
produces a colored urea product, was stopped with the addition of a 1:3:7 H​2​SO​4​ (96%):H​3​PO​4 
(85%): H​2​O solution to each well containing lysed cells. Urea concentration was then measured 
using a colorimetric urea assay measuring at a wavelength of 430 nm. A blank (lysis buffer) and 
1 mM urea solution were used as negative and positive controls, respectively, for the assay. 
 iNOS​ ​Assay (NO production): ​Activity of iNOS was measured in MDSCs using a 
Measure-iT High-Sensitivity Nitrite Assay Kit (Thermo Fisher Scientific). Cell lysates were 
plated onto conditioned media in 96-well plates and Measure-iT nitrite quantitation reagent was 
added, with media being incubated in reagent for 5 hours at room temperature. The reaction was 
then halted with the addition of 2.8 M NaOH solution, and the assay was read using fluorescence 
spectroscopy with a 365/450 nm excitation/emission wavelength. Concentrations of nitrite 
species produced were determined through comparison with a comparison with sodium nitrite 
standard solutions of eight different concentrations (0-55 μM). 
 ROS Assay: ​MDSCs collected in 96-well plates were stained with dichlorofluorescin 
diacetate (DCFDA), which, when oxidized, yields fluorescent dichlorofluorescin (DCF). Cells 
were incubated with DCFDA at 37​o​C for 120 minutes before DCF fluorescence was measured 
using 485/535 nm excitation/emission wavelength. 
 Genotyping:​ To ensure that all mice used in experiments were correctly labeled 
according to their genotype (WT or ​Mer​-/-​), PCR and gel electrophoresis were performed on cells 
extracted from clipped mouse tails using a TaKaRa La Taq Protocol (Takara) with primers 
specific for WT and knockout ​Mer ​alleles along with a neomycin-resistance cassette in order to 
differentiate between heterozygous WT and ​Mer​-/-​ mice (see appendix). PCR was performed to 
manufacturer’s specifications although primer concentrations of the PCR mixture being reduced 
from a final concentration of 0.2 μM to 0.1 μM in order to prevent primer dimerization and 
improve amplification of target genes. PCR products were run on 1% agarose gel containing 
ethidium bromide and imaged for UV fluorescence. 
 
  Western Blotting: ​Gel electrophoresis was performed on cell lysates from WT and ​Mer​-/- 
DC subsets with bands being resolved using SDS-PAGE gels. After semi-dry transfer to 
nitrocellulose paper, blots were incubated using protein-specific antibodies overnight according 
to manufacturer’s specifications (Cell Signaling Technology). The following day, blots were 
incubated in secondary anti-rabbit or anti-mouse antibodies, washed, and imaged using 
SuperSignal West Femto Maximum Sensitivity Substrate (Thermo Fisher Scientific). A BioRad 
Kaleidoscope protein ladder was used as a reference for identifying bands (BioRad). 
 
Results​: 
 
Based on the known role of TAM RTKs in reducing the inflammatory response, the 
expression of proteins associated with antigen presentation and immunosuppression were 
assessed with qRT-PCR and Western blot. Given the key roles the members of the TAM RTK 
family play in many immunosuppressive processes, knocking out these proteins should reduce 
the antigen presenting capability of these cells. First, the genotype of the knockout dendritic cells 
was confirmed using RT-qPCR by showing that ​Mer​ expression is reduced in ​Mer​-​/-​ and that 
Tyro3​ expression is reduced in ​Tyro3​-​/- ​DCs (Fig. 1A).  The production of RNA for TAM RTK 
ligand Protein S was also assessed, as knockout of receptor proteins is often associated with a 
compensatory overexpression of their ligands. This revealed an increase in ProS expression in 
Tyro3​-/-​ DCs (Fig. 1B) compared to Axl​-/-​, Mer​-/-​, and WT DCs. 
 Following the assumption that reduction in TAM RTK signaling in DCs would reduce 
antigen-presenting capacity and promote a tolerizing phenotype, the expression of genes 
associated with both processes in DCs were measured in ​Tyro3​-/-​, ​Axl​-/-​,​ ​Mer​-/-​, WT DCs using 
qRT-PCR to quantify mRNA levels. mRNA for IL-10, TRAF6, IDO, and PD-L1 was higher in 
TAM RTK-knockout DCs than WT counterparts (Fig. 2), indicating that TAM RTK signaling 
reduces the expression of the corresponding genes. Conversely, IFNɣ mRNA expression was 
reduced in all three knockout genotypes (Fig. 2), implying that TAM RTK signaling facilitates 
greater expression of this protein. 
In addition to the observed differences in mRNAs in TAM RTK knockout DCs, the 
expression of intracellular signaling proteins associated with the regulation of DC 
antigen-presenting activity was determined using Western blotting. The knockout of TAM-RTKs 
in DCs promoted an increase in the expression of STAT3, along with a concomitant increase in 
its phosphorylated form, pSTAT3. A similar effect was demonstrated for the protein complex 
SMAD 2/3 and its phosphorylated form, though the increase was only observed in ​Mer​-/-​ and 
Tyro3​-/-​ DCs. Although the expression of NF-κB was equal between WT and TAM-RTK 
knockout DCs, the expression of the protein’s phosphorylated form, pNF-κB, was virtually 
non-existent in WT DCs, but substantially increased in all three knockout genotypes (Fig. 3B). 
Together these results indicate that while TAM RTK signaling affects the expression of 
intracellular signaling proteins involved in antigen presentation, the three TAM RTKs each 
 
 affect the expression of different proteins, and TAM RTK signaling plays a role in both the 
expression and post-translational modification of proteins. 
While the differences in the expression of mRNAs and proteins associated with antigen 
presentation and tolerogenesis by DCs were notable, the combined effect of these changes on the 
ability of DCs to induce a T-cell response remained unknown.  A CyQuant T-cell Proliferation 
Assay Kit was used to assess the ability of DCs of various genotypes to stimulate the activity of 
both ​CD8​+​ T-cells and ​CD4​+​ T-regulatory cells. Incubation of DCs with ​CD4​+ ​cells resulted in a 
clear increase in proliferation of these cells in the presence of ​Mer​-/-​ and ​Tyro3​-/-​ DCs (Fig. 4A). 
Furthermore, incubation of ​CD8​+​ T-cells with DCs following a period of antigen uptake reduced 
the proliferation of the T-cells when cultured with a sufficient number of DCs (Fig. 4B). 
However, when CD8​+​ T-cells were co-cultured with DCs that did not have sufficient time for 
antigen uptake and the CD8+ T cells were processed no differences in T-cell proliferation were 
observed (Fig. 4C), and result consistent with the use of the non-uptake condition as a control. A 
significant decrease in proliferation was observed in the 40,000:200,000 condition in Tyro3​-/- 
condition, however this outlier is likely due to plate reader error or loss of T-cells through 
washing rather than a phenotyping difference in the ability of DCs to induce T-cell proliferation. 
Overall, these results imply that TAM RTK signaling promotes a DC-mediated inflammatory 
response, while knockout of the TAM RTKs reduces the ability of DCs to stimulate CD8​+​ T-cell 
activity and instead results in a tolerogenic response to antigens. 
As MDSCs primarily suppress the inflammatory response through the production of 
nitric oxide and reactive oxygen species (ROS), and through depletion of arginine in the local 
environment, these functions were measured in MDSCs of both WT and TAM RTK knockout 
genotypes using enzymatic assays. ROS production in both monocytic and granulocytic subsets 
was demonstrably reduced in all three knockout genotypes compared to WT (Fig. 5), with slight 
variation between ​Tyro3​-/-​, ​Axl​-/-​, and ​Mer​-/-​ MDSCs. While Axl​-/-​ iNOS activity, measuring nitric 
oxide production, was not significantly different between Axl​-/-​ and WT G-MDSCs, all other 
knockout cells demonstrated a reduction in iNOS activity compared to their WT counterparts 
(Fig. 6A). Furthermore, low dose (10 mg/kg) treatment of mice ​in vivo​ with Axl/Mer inhibitor 
UNC 2371 prior to MDSC harvesting resulted in a noticeable decrease in iNOS activity of 
MDSCs; however this effect was negated at higher doses (Fig. 6B). Finally, arginase activity, 
when assessed for the different subsets and genotypes of MDSC did not vary with the presence 
of TAM-family RTK expression (Fig. 7). 
To assess the underlying causes of the observed phenotypic differences in MDSCs, the 
expression of key intracellular signaling proteins involved with the immunosuppressive activity 
of MDSCs was measured using Western blots. While no clear differences were observed 
between WT and ​Mer​-/​-​ MDSCs of the same subset (Fig. 8A), there was a significant decrease in 
phosphorylation of Erk and P38 associated with knockout of ​Tyro3​ in both M-MDSCs and 
G-MDSCs (Fig. 8B). In ​Axl​-/-​ MDSCs, there was a significant reduction in STAT3 expression in 
G-MDSCs, and a clear decrease in P65 phosphorylation and Akt expression in both subsets of 
 
 MDSCs (Fig. 8C). These observed changes in protein expression support hypothesized role of 
TAM RTK signaling in regulation of immunosuppressive activity of MDSCs. 
 
Discussion​: 
 
Protein and mRNA Expression in DCs: ​Given the immunosuppressive role TAM RTKs were 
known to play in T-cells and macrophages, one would predict that knockout of these proteins in 
dendritic cells would produce a proinflammatory effect. In dendritic cells the immune response 
would be increased through heightened stimulation of cytotoxic T-cell activity, production of 
pro-inflammatory cytokines and other signaling proteins, and reduction in tolerogenic activity. 
Instead, from the qRT-PCR (Fig. 1A) it is apparent that knockout of TAM RTKs results in an 
increased expression of mRNAs for IL-10 and TRAF6, and a decreased IFN-ɣ expression. While 
TRAF6 has been implicated in the maturation of dendritic cells from myeloid precursors, IL-10 
is a potent anti-inflammatory signaling protein and IFN-ɣ activity promotes an anti-tumor 
response from T-cells.​5,16,19​ Additionally, there was a clear increase in expression of mRNAs for 
IDO and PD-L1 in all TAM RTK knock compared to WT (Fig. 1B), phenotypic changes with 
implications for DC function since IDO has been recognized as a promoter of the tolerogenic 
phenotype in DCs, and PD-L1 is associated with T-cell inactivation.​20,23​ Overall, these results 
indicate that TAM RTK signaling likely contributes to DC maturation, but that signaling through 
this pathway facilitates a shift in DCs from a tolerogenic (immunosuppressive) phenotype to an 
immuno-stimulatory one. 
In addition to differences in mRNA expression, TAM RTK DCs showed differences in 
the expression of a variety of key proteins in the regulation of antigen cross-presentation and 
CD8​+​ T-cell activation. The increases in STAT3/pSTAT3 expression and in NF-κB 
phosphorylation (Fig. 2) are seemingly paradoxical, as STAT3 activation is associated with the 
inhibition of antigen-presentation activity in DCs while activated NF-κB is crucial for 
antigen-presentation to occur.​22,25​ Additionally, there was an increase in the expression of both 
phosphorylated and unphosphorylated forms of the SMAD2/3 complex in Mer​-/-​ and Tyro3​-/- 
DCs. Due to the role of SMAD2/3, as a component of the TGF-β signaling pathway, in 
stimulating DC maturation and pro-inflammatory activity, DCs lacking Mer and Tyro3 likely 
exhibit greater antigen-presentation capability and potential to activate anti-cancer T-cell 
responses compared to WT cells. Together, these alterations in DC protein expression, while 
seemingly contradictory, indicate that the role of TAM RTK signaling in DCs may be more 
complex than initially believed. A repetition of Western blotting, including quantification using 
imageJ or similar software, to examine other members of the TGF-β, STAT3, and NF-κB 
signaling pathways would provide a better picture of how TAM RTK expression influences DC 
activation against cancer and other diseases. 
T-Cell Proliferation Assays: ​While differences in protein and mRNA expression in DCs may 
contribute to an alteration of the DC-mediated immune response, the ability of 
 
 antigen-presenting cells to induce greater CD8​+​ T-cell activity, while reducing CD4​+ 
T-regulatory cell activity, directly contributes to the ability of the immune system to destroy 
cancer cells. The ability of DCs to stimulate CD8​+​ T-cell proliferation following antigen uptake 
and processing is greatly reduced in cells lacking TAM RTKs when T-cells are incubated with a 
sufficient number of DCs (Fig. 4B). When compared to control (Fig 4C), the proliferation of 
CD8​+​ T-cell is greatly increased due to the direct activation of T-cells by the influenza peptide 
relative to the activity stimulated by antigen-presentation (Fig 4B). Overall, the lack of 
significant differences in proliferation in the control indicates that differences observed in the 
experimental condition are due to differences in the ability of DCs to stimulate proliferation 
through antigen-presenting activity, rather than release of cytokines or metabolic activity of DCs 
themselves. Ultimately, the decrease in CD8​+​ T-cell proliferation in Fig 4B evinces a reduction 
in cross-presentation capacity because cross-presentation is critical for the direct activation of 
CD8​+​ T-cells by DCs. Inhibiting TAM RTK signaling of DCs in cancer treatment would thus 
reduce the cytotoxic T-cell response to the disease, and could make such treatment less 
effective.​12​ Additionally, there was an observed increase in CD4​+​ T-cell proliferation following 
incubation with Mer​-/-​ and Tyro3​-/-​ DCs (Fig. 4A). CD4​+​ is a marker of both T-regulatory cells, 
which reduce the response of cytotoxic T-cells to cancer, and helper T-cells, which contribute to 
an increased anti-tumor response. The increase in CD4​+​ T-cell proliferation following Mer TK 
knockout is consistent with previous results, which were attributed to a decrease in helper T-cell 
proliferation and activity.​26​ Thus, the increase in CD4​+​ T-cell proliferation likely corresponds to 
increased helper T-cell activity with reduced Mer or Tyro3 signaling, meaning that knockout of 
these proteins would promote a more robust immune response through CD4​+​ activity. However, 
the increase in CD4​+​ cell could also be attributed to an increase in T-regulatory cell proliferation, 
as these cells also express CD4. Such an increase would reduce in the anticancer immune 
response, so it is necessary to differentiate between the two cell types when assessing the effects 
of TAM RTK inhibition.​13​ Future experiments will require proper characterization of the 
expanded CD4​+​ T-cell population using flow cytometry to screen cells for both CD4 and 
FOXP3, a marker specific to T-regulatory cells. If in fact the increase in CD4​+​ cells can be 
attributed to T-regulatory cells, the tendency for DCs with fully functional and impaired TAM 
RTK signaling to induce different types of T-cells would indicate a shift to a more tolerogenic 
state following a decrease in TAM RTK signaling in DCs. This result would run counter to our 
initial hypothesis and would imply that inhibition of TAM RTK signaling should be avoided to 
promote greater stimulation of T-cells by DCs as part of an anti-cancer immune response. On the 
other hand, if the increase in CD4​+​ T-cells is due to helper T-cell proliferation, the results of the 
CD4​+​ and CD8​+​ T-cell proliferation assays would be contradictory, indicating that a reevaluation 
of the methods would be necessary to accurately gauge the role of TAM RTK signaling on 
DC-mediated T-cell proliferation. The procedure used (see Methods) required multiple washes 
on weakly adherent T-cells in a 96-well plate, so the observed decrease in CD8​+​ T-cells may 
have been a result of loss of T-cells in the wash rather than an actual decrease in CD8​+​ T-cell 
 
 proliferation. A dye-dilution assay employing flow cytometry or ​3​H-labeled thymidine 
incorporation assay would avoid this problem and might provide a more accurate assessment of 
CD8​+​ T-cell proliferation by both WT and TAM RTK knockout DCs. 
Enzymatic Assays of MDSC Activity: ​As we initially hypothesized, knockout of each of the 
three TAM RTKs in MDSCs produced a significant decrease in the production of reactive 
oxygen species (ROS) by both monocytic (M-MDSC) and granulocytic (G-MDSC) subsets, with 
the Tyro3​-/-​ MDSCs of both subsets showing the greatest difference compared to WT (Fig. 5). 
Furthermore M-MDSCs lacking each of the TAM RTKs demonstrated a reduced ability to 
produce nitric oxide. Because ROS and NO produced by MDSCs react with each other ​in vivo​ to 
produce peroxynitrate species capable of deactivating CD8​+​ T-cells in the tumor 
microenvironment by nitrosylating T-cell receptors, decreased TAM RTK signaling may reduce 
the immunosuppressive ability of MDSCs in a synergistic fashion.​3,4​ Moreover, the decrease in 
constitutive MDSC iNOS activity observed with treatment of mice with 10 mg/kg of UNC 2371 
(Fig. 6B) reveals that the phenotypic difference in immunosuppressive activity of MDSCs can be 
approximated in WT by inhibiting TAM RTK signaling with a drug. The increase in endogenous 
nitric oxide production associated with higher doses of UNC 2371 is likely due to non-specific 
binding to other cellular regulators of iNOS, and further refinement of the inhibitors used will 
increase the specificity of inhibitors for TAM RTKs, improving the ability of the drugs to inhibit 
MDSC-mediated immunosuppression. 
 Enzymatic assays also revealed that arginase activity, as measured by the conversion of 
arginine into urea, is not significantly different in Axl​-/-​ and Tyro3​-/-​ MDSCs. While this result is 
inconsistent with our hypothesis due to the role of arginase in reducing cytotoxic T-cell activity 
in the tumor microenvironment through depletion of arginase,​2​ this result indicates that the role 
of arginase is less important than NO and ROS production on the TAM RTK-mediated 
immunosuppressive activity of MDSCs. Overall, the lack of difference in arginase activity would 
have little effect on the viability of TAM RTK inhibition as a means of increasing the anticancer 
immune response by reducing the activity of MDSCs due to the reduction in the other 
immunosuppressive mechanisms of those cells. 
Protein Expression in MDSCs: ​To explain the underlying mechanisms behind the effect of 
TAM RTK signaling on MDSC activity, protein expression was assessed with Western blotting. 
While the results of Mer TK knockout were difficult to discern using this method, the clear 
reduction in phosphorylation of Erk and P38 in Tyro3​-/-​ MDSCs supports the hypothesis that 
TAM RTK signaling facilitates the immunosuppressive function of MDSCs, since intracellular 
signaling pathways involving Erk and P38 are associated with greater MDSC proliferation in 
tumor-bearing mice.​26​ In Axl​-/-​ MDSCs, the decrease in expression of STAT3 (both 
phosphorylated and unphosphorylated in G-MDSC), Akt, and pNF-ÔB also supports the 
observed phenotypic changes due to the role of STAT3, Akt, and NF-кB signaling pathways in 
the immunosuppressive activity of MDSCs.​26 
 
 Ultimately, while the role of TAM RTK signaling in DCs requires further evaluation in 
the context of cancer treatment, an inhibition of TAM RTK signaling likely contributes to greater 
immunosuppression by MDSCs. TAM RTK inhibitors may promote anticancer immune 
responses and improve survival if applied as part of a larger immunotherapy regimen. 
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Figure 1- Expression of TAM RTKs and Ligands in DCs Confirms TAM RTK Knockout 
Data were obtained using qPCR to quantitate mRNA expression in murine ​CD11c​+​ ​DCs of 
indicated phenotypes. Splenic DCs were harvested from mice, and RT-PCR was performed on 
extracted RNA to generate cDNA for use in qPCR. mRNA expression was quantified by 
comparison to known standards for each of the indicated mRNAs. ​A.​ Expression of Axl and Mer 
TK was quantified in TAM RTK-knockout RTKs and WT control. ​B.​ Expression of TAM RTK 
ligand Protein S (ProS) in TAM RTK-knockout and WT mice. 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2- Expression of Immune Cell Signaling Proteins Varies with Genotype 
Data were obtained using qPCR to quantitate mRNA expression in murine ​CD11c​+​ ​DCs of 
indicated phenotypes. Splenic DCs were harvested from mice, and RT-PCR was performed on 
extracted RNA to generate cDNA for use in qPCR. mRNA expression was quantified using a 
ΔΔC​T​ method to compare mRNA levels to a GAPDH control. Bars indicate standard error, and 
A. ​Expression of interferon-ɣ, IL-10, IL-12, TRAF6, and VEGF was quantified in DCs ​B.​ IDO, 
PD-L1, and PGE-2 expression was assessed. Bars are labelled to indicate the number of samples 
analyzed. 
 
  
 
 
 
 
 
 
 
 
 
 
 
Figure 3- TAM RTK Signaling Alters Expression of Intracellular Signaling Proteins 
Western blotting was performed on murine ​CD11c​+​ ​DCs of indicated phenotypes, using 
antibodies for proteins associated with altered cross-presentation capacity and tolerizing 
phenotype. Splenic DCs were harvested from mice then lysed, and the lysate was run out on a 
10% polyacrylamide gel before being transferred to a nitrocellulose membrane. ​A.​ Blot was used 
to assess expression of STAT3 / pSTAT3, SMAD2/3 / pSMAD2/3, and β-catenin with actin 
control. ​B.​ The extent of phosphorylation of NF-κB was determined and compared to actin 
control. 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4- Suppression of TAM-RTK Signaling Promotes a Tolerizing Phenotype in DCs 
The extent of T-cell proliferation was assessed using a CyQuant T-cell proliferation assay. ​A. 
OT-1 CD4​+​ T-cells harvested from mice were incubated with DCs of the indicated phenotype 
and influenza peptide in a 240,000:40,000 ratio for three days before analysis. ​B. ​Dendritic cells 
were incubated with influenza peptide for a two day period and media was replaced. CD8​+ 
T-cells were then added to DCs in 240,000:40,000 and a control (200,000:40,000) ratio, and cells 
were incubated for three more days. ​C.​ To control for direct stimulation of OT-1 CD8​+​ ​T-cells 
by influenza peptide, T-cells were simultaneously incubated with influenza peptide and DCs in 
the indicated ratios. 
 
 
 
 
 
  
Figure 5-ROS Production Occurs at Lower Levels in TAM RTK Knockout Mouse MDSCs 
Cells extracted from bone marrow of tumor-bearing mice were sorted using FACS and grown in 
culture before ROS concentrations were measured using a DCFDA fluorescent assay kit, where 
fluorescence was measured at 540 nm detection wavelength. Indicated cells subsets were treated 
with UNC 4241 Mer TK inhibitor  ​in vitro​ prior to assay to compare with vehicle-treated cells 
(labelled VT). Cell samples were analyzed in triplicate, and error bars represent SEM. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6- iNOS Activity Declines with Knockout of Mer TK, Tyro3 TK 
A.​ ​Both varieties of MDSCs extracted from WT and TAM RTK knockout mice were measured 
for immune nitrite oxide synthase (iNOS) activity. Cells were treated ​in vivo​ with the Axl/Mer 
inhibitor UNC 4241 (Earp Lab) and compared to vehicle treated (VT) cells. ​B.​ Tumor-bearing 
mice were treated for a period of 10-15 days (from first palpable appearance of the tumor until it 
reached a diameter of 15 mm) with UNC 2371, a Mer TK inhibitor (Earp Lab), in the dosages 
indicated above, and iNOS activity was measured in these cells. 
 
  
Figure 7-Arginase Activity Patterns Vary between MDSC Genotypes 
 
Cells extracted from tumor-bearing mice of different genotypes were sorted into both subsets of 
MDSCs, and the levels of arginase activity in those cells were analyzed using a colorimetric 
assay. Some of the samples were treated ​in vitro​ with UNC 4198, a Mer/Tyro3 inhibitor (Earp 
Lab) for comparison with vehicle-treated (VT) MDSCs of their respective genotype and subset 
in the inhibitory concentrations listed above (IC50 MerTK= 0.98 nM, Axl= 5.5 nM, Tyro3= 0.56 
nM). Samples were analyzed in triplicate, and error bars represent SEM. 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
Figure 8-Expression of Intracellular Signaling Proteins is Affected by TAM RTK Signaling 
 
Western blots were used to assess levels of expression of proteins critical for immunosuppressive 
activity and maturation in MDSCs of various genotypes. ​A. ​WT and Mer​-/-​ MDSCs of both 
monocytic and granulocytic subsets were compared with a focus on the phosphorylation and 
expression of STAT3, ERK, and P38. Actin expression was used to ensure equal loading of 
wells. ​B.​ Levels of ERK/p-ERK and P38/p-P38 were assessed in WT and ​Tyro3​-/-​ ​MDSC subsets 
C.​ The expression of various cell signaling proteins was compared in WT and ​Axl​-/-​ MDSCs, and 
blots were standardized by using an actin control. 
 
 
 
 
 
 
 Appendix​:  
 
Table 1- Primer Sequences Used in PCR: 
Gene of Interest Forward Primer 
Sequence (5’-3’) 
Reverse Primer  
Sequence (5’-3’) 
Tyro3 GCCTCCAAATTGCCCGTCA CCAGCACTGGTACATGAGATCA 
Axl  ATGGCCGACATTGCCAGTG CGGTACTAATCCCCGTTGTAGA 
Mer  CAGGGCCTTTACCAGGGAGA TGTGTGCTCCATGTGATCTTC 
Gas6 TGCTGGCTTCCGAGTCTTC CGGGGTCGTTCTCGAACAC 
ProS CGCTTTCGGGTGCTACTGG CACTCTCGTTCAAGGTTGCC 
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